Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT ID: NCT04202341
Last Updated: 2025-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2019-12-02
2029-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitaccess Real MG Registry
NCT06064461
Myasthenia Gravis Foundation of America Global MG Patient Registry
NCT06617741
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
NCT00727194
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
NCT06764160
The Impact of Myasthenia Gravis in the Real World
NCT04176211
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Capable of giving signed informed consent, which includes compliance with the protocol requirements and restrictions.
3. Participants must have myasthenia gravis historical data, such as MG-ADL and MGFA class, available to be enrolled in the Registry.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexion Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Site
Birmingham, Alabama, United States
Clinical Trial Site
Scottsdale, Arizona, United States
Clinical Trial Site
Fresno, California, United States
Clinical Trial Site
Orange, California, United States
Clinical Trial Site
Rancho Mirage, California, United States
Clinical Trial Site
Sylmar, California, United States
Clinical Trial Site
Colorado Springs, Colorado, United States
Clinical Trial Site
Fort Collins, Colorado, United States
Clinical Trial Site
New Haven, Connecticut, United States
Clinical Trial Site
Washington D.C., District of Columbia, United States
Clinical Trial Site
Clearwater, Florida, United States
Clincal Trial Site
Gainesville, Florida, United States
Clinical Trial Site
Jacksonville, Florida, United States
Clinical Trial Site
Tampa, Florida, United States
Clinical Trial Site
Augusta, Georgia, United States
Clinical Trial Site
Iowa City, Iowa, United States
Clinical Trial Site
Lexington, Kentucky, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Lansing, Michigan, United States
Clinical Trial Site
Columbia, Missouri, United States
Clinical Trial Site
New Hyde Park, New York, United States
Clinical Trial Site
Chapel Hill, North Carolina, United States
Clinical Trial Site
Charlotte, North Carolina, United States
Clinical Trial Site
Durham, North Carolina, United States
Clinical Trial Site
Dayton, Ohio, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Chattanooga, Tennessee, United States
Clinical Trial Site
Knoxville, Tennessee, United States
Clinical Trial Site
Dallas, Texas, United States
Clinical Trial Site
Houston, Texas, United States
Clinical Trial Site
Burlington, Vermont, United States
Clinical Trial Site
Milwaukee, Wisconsin, United States
Clinical Trial Site
Vienna, , Austria
Clinical Trial Site
Brampton, Ontario, Canada
Clinical Trial Site
London, Ontario, Canada
Clinical Trial Site
Montreal, Quebec, Canada
Clinical Trial Site
Chengdu, Sichuan, China
Clinical Trial Site
Beijing, , China
Clinical Trial Site
Changchun, , China
Clinical Trial Site
Chengdu, , China
Clinical Trial Site
Guangzhou, , China
Clinical Trial Site
Jinan, , China
Clinical Trial Site
Nanchang, , China
Clinical Trial Site
Qingdao, , China
Clinical Trial Site
Shijiazhuang, , China
Clinical Trial Site
Hanover, Hannover, Germany
Clinical Trial Site
Milan, , Italy
Clinical Trial Site
Naples, , Italy
Clinical Trial Site
Abhā, , Saudi Arabia
Clinical Trial Site
Jeddah, , Saudi Arabia
Clinical Trial Site
Riyadh, , Saudi Arabia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALXN-MG-501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.